An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT

Current Research in Translational Medicine - Tập 67 - Trang 79-88 - 2019
P.J. Hayden1, T. Sirait2, L. Koster2, J.A. Snowden3, I. Yakoub-Agha4
1Dept. of Haematology, Trinity College Dublin, St. James’s Hospital, Dublin 8, Ireland
2EBMT Data Office, 2300 Leiden, the Netherlands
3Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
4CHU de Lille, LIRIC, INSERM U995, Université de Lille, 59000, Lille, France

Tài liệu tham khảo

June, 2018, Chimeric antigen receptor therapy, N Engl J Med, 379, 64, 10.1056/NEJMra1706169 Gauthier, 2017, Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives, Curr Res Transl Med, 65, 93, 10.1016/j.retram.2017.08.003 Quesnel, 2018, CAR T-cells: A John von Neumann legacy?, Curr Res Transl Med, 66, 35, 10.1016/j.retram.2018.04.002 Maude, 2018, Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Grupp, 2018, Beginning the CAR T cell therapy revolution in the US and EU, Curr Res Transl Med, 66, 62, 10.1016/j.retram.2018.03.004 Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980 Neelapu, 2017, Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Ghobadi, 2018, Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma, Curr Res Transl Med, 66, 43, 10.1016/j.retram.2018.03.005 Yakoub-Agha, 2018, Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), Curr Res Transl Med, 66, 57, 10.1016/j.retram.2018.04.001 Buitrago, 2019, Adult survivorship: considerations following CAR T-Cell therapy, Clin J Oncol Nurs, 23, 42 Callahan, 2019, Pediatric survivorship: considerations following CAR T-Cell therapy, Clin J Oncol Nurs, 23, 35 Rubin, 2019, Neurological toxicities associated with chimeric antigen receptor T-cell therapy, Brain, 10.1093/brain/awz053 Gauthier, 2018, Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy, Curr Res Transl Med, 66, 50, 10.1016/j.retram.2018.03.003 Perica, 2018, Building a CAR garage: preparing for the delivery of commercial CAR t cell products at memorial sloan kettering Cancer center, Biol Blood Marrow Transplant, 24, 1135, 10.1016/j.bbmt.2018.02.018 Taylor, 2019, Building a program: implications for infrastructure, nursing education, and training for CAR T-Cell therapy, Clin J Oncol Nurs, 23, 20